TWST — Twist Bioscience Corporation stock price, charts and financials

QT81Twist Bioscience Corporation

Twist Bioscience Corporation (NASDAQ: TWST) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
123.84
+8.17+7.06%
OverviewShort InterestFilings
TWSTQT81Twist Bioscience Corporation·NASDAQ
123.84+7.06%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QGEN+4.07%$44.02RDNT+6.44%$77.05SHC-0.11%$18.84BLLN+4.90%$97.96ICLR+0.51%$165.35CRL+1.70%$272.04RVTY+1.37%$116.23VCYT-1.95%$46.30
Snapshot
Index-P/E-EPS (ttm)-1.33Insider Own4.02%Shs Outstand62.27MPerf Week26.35%
Market Cap7.20BForward P/E-EPS next Y-1.40Insider Trans-16.50%Shs Float59.69MPerf Month23.49%
Enterprise Value7.18BPEG0.80EPS next Q-Inst Own126.08%Short Float23.65%Perf Quarter97.59%
Income-136.14MP/S16.68EPS this Y-62.40%Inst Trans-Short Ratio8.09Perf Half Y145.58%
Sales431.80MP/B16.19EPS next Y35.08%ROA-20.33%Short Interest14.12MPerf YTD264.66%
Book/sh-P/C-EPS next 5Y-ROE-29.89%52W High126.67 -2.24%Perf Year346.60%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-24.57%52W Low24.94 396.44%Perf 3Y440.77%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.72% 33.17%Gross Margin51.97%Volatility11.05% 7.84%Perf 5Y-6.00%
Dividend TTM-EV/Sales16.63EPS Y/Y TTM63.06%Oper. Margin-31.91%ATR (14)8.11Perf 10Y-
Dividend Ex-Date-Quick Ratio2.38Sales Y/Y TTM30.99%Profit Margin-31.66%RSI (14)67.69Recom2.29
Dividend Gr. 3/5Y-Current Ratio2.67EPS Q/Q5.66%SMA2021.47%Beta2.15Target Price104.67
Payout0.00%Debt/Eq0.21Sales Q/Q19.35%SMA5031.04%Rel Volume0.89Prev Close115.67
Employees979LT Debt/Eq0.26EarningsNov 13SMA200112.19%Avg Volume1.75MPrice123.84
IPO DateOct 31, 2018Option/ShortYes / YesEPS/Sales Surpr.-19.72% 1.78%Net Debt/EBITDA0.22Volume1,561,519Change7.06%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedPiper SandlerOverweight$85 → $115
Aug-04-26ReiteratedRobert W. Baird$113 → $115
Jul-16-26ReiteratedLeerink PartnersOutperform$80 → $110
Jul-14-26ReiteratedCanaccord GenuityBuy$90 → $120
Jul-06-26DowngradeEvercore ISI GroupOutperform → In Line$52 → $102
Jun-29-26ReiteratedGuggenheimBuy$60 → $107
Jun-24-26ReiteratedBarclaysOverweight$65 → $95
Jun-15-26ReiteratedCowen & Co.Outperform$68 → $89
Jun-15-26InitiatedCanaccordBuy$90
Jun-15-26ReiteratedUBS$89
Latest News
Aug-06-26
Aug-06-2603:14AM
Twist Bioscience (NASDAQ:TWST) Shares Up 10.3% After Analyst Upgradedefenseworld.net
Aug-05-26
Aug-05-2611:57AM
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115Benzinga
10:08AM
Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safetyseekingalpha.com
12:00AM
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stockgurufocus.com
Aug-04-26
Aug-04-2604:01PM
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stockbusinesswire.com
08:00AM
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)businesswire.com
04:05AM
First Trust Advisors LP Acquires New Holdings in Twist Bioscience Corporation $TWSTdefenseworld.net
Aug-03-26
Aug-03-2602:39PM
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcriptseekingalpha.com
12:13PM
Twist Bioscience Sees AI Drug Discovery Pipeline Expandbenzinga.com
11:03AM
Twist Bioscience Q3 Earnings Call Highlightsmarketbeat.com
09:26AM
Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimateszacks.com
08:00AM
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Resultsgurufocus.com
Jul-21-26
Jul-21-2603:07AM
Allspring Global Investments Holdings LLC Purchases Shares of 455,446 Twist Bioscience Corporation $TWSTdefenseworld.net
Jul-19-26
Jul-19-2610:53AM
Thrivent Small Cap Growth Fund Q2 2026 Portfolio ReviewSeekingAlpha
Jul-15-26
Jul-15-2601:56PM
Artisan Mid Cap Fund Q2 2026 Performance ReviewSeekingAlpha
Company

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Ownership
Total institutional ownership126.08%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue432377313——————
Cost of Goods Sold Incl. D&A208186180——————
Gross Profit224191133——————
Selling, General and Administrative Excl. Other291247218——————
Research and Development728091——————
Other Operating Expense0045——————
Operating Income-138-136-221——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)35913——————
Net Income Before Taxes-136-77-208——————
Income Taxes011——————
Consolidated Net Income-137-78-209——————
Net Income From Continuing Operations-136-78-209——————
Net Income-137-78-209——————
EPS (Recurring)-2.22-1.30-3.60——————
EPS (Basic, Before Extraordinaries)-2.22-1.30-3.60——————
EPS (Diluted)-2.22-1.30-3.60——————
EBITDA-108-52-177——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio17.774.488.37——————
Gross Margin51.8550.6642.49——————
Operating Margin-31.94-36.07-70.61——————
Net Margin-31.71-20.69-66.77——————
Shares Outstanding626058——————
Market Capitalization7,6781,6882,620——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$129.40$99.66$69.91$40.17$10.43● Close Price0.00M2.09M4.17M6.26M8.34MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cho DennisSee RemarksAug 05 '26Sale109.7514,2051,558,99989,866Aug 07
Finn Patrick JohnPresident and COOAug 03 '26Sale85.322,888246,408269,678Aug 05
Green PaulaSVP of Human ResourcesAug 03 '26Sale85.321,13396,669119,281Aug 05
Leproust Emily M.Chief Executive OfficerAug 03 '26Sale85.325,101435,223818,938Aug 05
WERNER ROBERT F.Chief Accounting OfficerAug 03 '26Sale85.3216714,24946,160Aug 05
Cho DennisSee RemarksAug 03 '26Sale85.321,07091,294104,071Aug 05
Finn Patrick JohnPresident and COOJul 23 '26Sale93.892,238210,133272,566Jul 27
Laponis AdamChief Financial OfficerJul 09 '26Sale94.332,399226,307110,276Jul 13
Leproust Emily M.Chief Executive OfficerJun 25 '26Sale95.0018,8801,793,600824,039Jun 26
Cho DennisSee RemarksJun 24 '26Sale89.7514,2051,274,899105,141Jun 26
Green PaulaSVP of Human ResourcesJun 22 '26Sale87.3229125,411120,414Jun 24
Cho DennisSee RemarksJun 22 '26Sale87.3234630,214119,346Jun 24
Leproust Emily M.Chief Executive OfficerJun 22 '26Sale87.321,688147,400842,919Jun 24
Green PaulaSVP of Human ResourcesJun 15 '26Option Exercise23.3326,137609,776146,842Jun 17
Green PaulaSVP of Human ResourcesJun 15 '26Sale81.6726,1372,134,488120,705Jun 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.